Transforming dental care with Ambrilux Dental Gel™
Overview
Oral Biolife, Inc. is transforming dental care with Ambrilux Dental Gel™, a non-invasive, regenerative treatment that reduces inflammation and stimulates bone growth by harnessing the piezoelectric effect. Ambrilux Dental Gel offers a breakthrough solution for both human and companion animal health. Backed by a strong U.S. patent and broad industry support, Ambrilux represents a significant advancement in periodontal therapy. Phibro Animal Health, OBL’s animal health partner will launch Ambrilux in the companion animal market in Q4 2025. With a strategic regulatory path and established distribution partnerships, Oral Biolife is positioned for human market entry by mid 2027. Led by experienced professionals and a world-class advisory board, Oral Biolife is addressing a multi-billion-dollar market opportunity. The company is currently closing its $2 million seed round to accelerate commercialization and advance its mission to revolutionize oral health.
Currently raising: $700k
Founder: Bill Breitenbach and Greg Ambra
Discovery
The social economy where attention creates real value.
WAHA transforms advertising into direct rewards for users, creators, artists, and businesses through an incentive-powered social platform.
AI native referral hiring systems
Fixing hiring, for everyone
E.V. Sharing Serice.
The E.V. Sharing Service imitates the Bicycle Sharing Service, but with E.V.s.
AI Platform to accelerate deal velocity for B2B sales teams
AI-edited demo trailers, buyer-facing digital sales rooms, and auto-fired handoff briefs, all in one workspace from first call to closed deal.
Request a warm introduction to the Oral Biolife team through the Ascent Valley network. Open to investors approved on application.